Your Global Leader in Stem Cell Market Research
26 August 2019, Melbourne, Australia: Regenerative medicine company Exopharm Limited (ASX:EX1) announces the start of the PLEXOVAL Phase 1 study, the first human clinical trial using exosomes for wound healing. [Read more…]
With autism spectrum disorder (ASD) affecting between 1-2% of the population and affecting all racial, ethnic, and socioeconomic groups, the condition is becoming of global importance. While the pharma industry has not yet been able to deliver a solution for this disease, the cell therapy industry is now undertaking the challenge. [Read more…]
ATLANTA and DETROIT, January 23, 2019 – NeurExo Sciences, LLC (NXS), a biopharmaceutical company and subsidiary of NeuroTrauma Sciences, LLC, will be hosting a teach-in event featuring leading exosome researcher, Michael Chopp, Ph.D., Vice Chairman, Department of Neurology and Scientific Director, Neurosciences Institute, Zoltan J. Kovacs Chair of Neuroscience Research at Henry Ford Health System (HFHS), Detroit, and Distinguished Professor of Physics, Oakland University (MI). Dr. Chopp’s presentation will provide a primer and overview of exosomes, small extracellular vesicles that provide a means of mediating intercellular communication. He also will focus on his team’s pioneering technology employing exosomes engineered with enriched microRNA for the purpose of treating neurological disease and injury, including stroke and traumatic brain injury (TBI). [Read more…]
JERUSALEM, Jan. 2, 2019 — Stem Cell Medicine Ltd. (SCM), a biotechnology company developing new therapies for neurological indications, including mesenchymal stem cells and anti-BMP molecules for the treatment of Multiple Sclerosis, and gene therapy for the treatment of neuropathic pain, has licensed an innovative exosomes based technology for the treatment of neurodegenerative and neuropsychiatric indications, specifically, autism spectrum disorder (ASD). The treatment is based on vesicles, exosomes, derived from adult stem cells (MSC-exo) that are administered intranasally. The technology was developed by Professor Dani Offen, Sackler School of Medicine, Sagol School of Neurosciences Tel Aviv University and was licensed from Ramot, the Business Engagement Center at Tel Aviv University. [Read more…]
In recent months, exosome start-up companies have been the recipients of approximately $386.2 million in investor funding. Clearly, investors are feeling favorable toward companies developing exosome products and there is a growing belief that the industry is poised for growth.
To date, four companies have dominated the exosome funding world. These companies are:
